Format

Send to

Choose Destination
See comment in PubMed Commons below
Epidemiology. 2004 Jan;15(1):100-4.

Estrogen replacement therapy and ovarian cancer.

Author information

  • 1Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota55454-1015, USA. folsom@epi.umn.edu

Abstract

BACKGROUND:

A recent meta-analysis concluded that there was no overall association between estrogen replacement therapy (ERT) and risk of epithelial ovarian cancer. However, several subsequent studies have suggested that long-term ERT could increase ovarian cancer risk.

METHODS:

We prospectively examined the association of ERT with epithelial ovarian cancer among 31,381 postmenopausal women in Iowa followed for 15 years.

RESULTS:

Women who were using ERT at baseline had an elevated multivariate-adjusted relative risk of ovarian cancer (1.7; 95% confidence interval [CI] = 1.1-2.8) compared with never-users. Risk was higher among women who had been using ERT at baseline for more than 5 years (2.5; CI = 1.4-4.5). A time-dependent analysis likewise yielded a relative risk of 1.7 for current ERT use. Former ERT use was not associated with ovarian cancer incidence.

CONCLUSIONS:

Long duration of ERT use after menopause could increase the risk of epithelial ovarian cancer.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk